Biomedical Research VISIT Biomed Research Site
Our clinical and basic research projects involve multidisciplinary areas like clinical biochemistry, molecular biology, pharmacology and toxicology. Recently we have evaluated the utility of combined values of serum fructosamine and fasting/random blood glucose for identification of high risk diabetic patients. We have also suggested the efficacy of HbA1c in predicting dyslipidemia besides its primary role in monitoring long-term glycemic control. The findings of our basic research have shown the protective effects of anti-inflammatory and antioxidant drugs in experimental gastric lesions. We have noticed that drugs with the ability to down-regulate inflammatory cascade can have beneficial effects in septic shock. Using a mouse model of Parkinson’s disease, we concluded that an early-stage proinflammatory cascade may lead to subsequent neurodegeneration. An important role of phospholipase A2 (PLA2) in experimental parkinsonism was also suggested by showing significant reversal of MPTP and 6-OHDA induced dopaminergic toxicity by PLA2 inhibitor quinacrine. In a recent investigation, we noticed that inhibition of cholinergic neurotransmission by nicotine may have beneficial effects in experimental Huntington’s disease. We also observed protective effects of dopamine antagonist and antioxidants in experimental movement disorders. Our studies in rodents have shown that advancing age and gentamicin enhance the behavioral syndrome caused by a prototype nitrile compound. We also demonstrated protective effects of antioxidants in cyclosporine-induced nephrotoxicity and the adverse effects of aluminum and caffeine in experimental neurotrauma. Besides above pharmacological research I have also developed methodologies for genotyping, gene expression analysis, enzyme assays, polyamines analysis and ATP estimation.